Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
Phase 3
Completed
- Conditions
- Secondary PreventionVenous Thromboembolism
- Interventions
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 214
- Registration Number
- NCT02197416
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇨🇦Kingston General Hospital, Kingston, Ontario, Canada
🇱🇹Children Intensive Care Hosp,Anaesthesiology Dept,Vilnius, Vilnius, Lithuania
Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 189426
- Registration Number
- NCT02197078
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02195466
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT02195804
Use of Synvisc® in Knee Osteoarthritis - Survey on Practice
Completed
- Conditions
- Osteoarthritis
- Interventions
- Drug: Synvisc®
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT02195544
A Prescription-Event Monitoring (PEM) Study of Tiotropium
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13891
- Registration Number
- NCT02196194
Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 374
- Registration Number
- NCT02195505
Retrospective Follow-up Study of Synvisc® in Patients With Knee Osteoarthritis
Completed
- Conditions
- Osteoarthritis
- Interventions
- Drug: Synvisc®
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02195557
Retrospective Follow-up of Synvisc® in Active Patients With Knee Osteoarthritis
Completed
- Conditions
- Osteoarthritis
- Interventions
- Drug: Synvisc®
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT02195492
Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-cyclohexane ambroxol oral solutionDrug: [14C]-benzyl ambroxol oral solution
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02194257
© Copyright 2025. All Rights Reserved by MedPath